Skip to main content

Table 2 Patients distribution of mRS score on day 90 before and after MAIC

From: Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective

mRS score

Dl-3-n-butylphthalide

Edaravone dexborneol

Before MAIC

After MAIC

mRS 0–1

63.80%

67.10%

67.00%

mRS 2–5

36.20%

32.90%

33.00%

mRS 6

0.00%

0.00%

0.00%

  1. MAIC Matching-adjusted indirect comparison, mRS Modified Rankin scale
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us